Electrochemical Aptamer-Based Sensors for In Vivo Pharmacokinetic Monitoring of Anthracycline Chemotherapeutics: Mechanisms, Stability, and the Clinical Translation Landscape
Electrochem · 21.07.2026 · 7 (3) · 20
DOI: 10.3390/electrochem7030020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Electrochem, online erschienen am 21.07.2026. Verfasst von Haoran Zhang und 3 weiteren Autor:innen. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Area Project of General Universities in Guangdong Province.
Abstract (Originalsprache)
Anthracycline agents, principally doxorubicin and daunorubicin, are widely used in oncology yet carry a narrow therapeutic index and pronounced interindividual pharmacokinetic variability that exposes patients simultaneously to the risk of subtherapeutic dosing and cumulative cardiotoxicity. Conventional therapeutic drug monitoring (TDM) based on periodic venous sampling and offline high-performance liquid chromatography cannot resolve the sub-minute concentration dynamics that determine organ-specific drug exposure. Electrochemical aptamer-based (EAB) sensors couple nucleic-acid aptamers, self-assembled monolayers, and methylene blue redox reporters on gold microelectrodes to convert binding-induced conformational changes into real-time, reagent-free electrochemical signals. Recent advances in this field fall into five areas: signal interrogation strategies, from kinetic differential measurement to calibration-free Fourier-transform impedance spectroscopy (FFT-EIS); interface engineering including nanostructured electrodes and AI-guided aptamer design; in vivo multi-compartment pharmacokinetic monitoring and closed-loop feedback drug delivery; the mechanisms of in vivo signal drift alongside antifouling countermeasures spanning hydrogel barriers, zwitterionic brushes, and xenonucleic acid backbone substitution; and FDA premarket pathways and clinical translation, including Premarket Approval requirements and the emerging Real-Time Clinical Trial (RTCT) framework. In live rodents, dual-compartment monitoring has resolved a reproducible 30–60 min plasma-to-ISF lag for doxorubicin at 12 s temporal resolution; calibration-free FFT-EIS interrogation achieves inter-animal coefficients of variation below 12% without individual pre-calibration; and xenonucleic acid backbone substitution has extended continuous in vivo operation to seven consecutive days. Unlike prior EAB reviews that survey general molecular targets or benchtop aptasensors, this review uniquely integrates anthracycline-specific in vivo pharmacokinetics, multi-compartment plasma–ISF monitoring, calibration-free interrogation, XNA-enabled long-term stability, and FDA/RTCT regulatory translation into a single clinical roadmap. Three gaps still separate rodent proof-of-concept work from chemotherapy patients: clinical-context validation, tumor microenvironment calibration, and anthracycline-specific XNA aptamer design.
Förderung
- Key Area Project of General Universities in Guangdong Province
Zitieren
APA
Zhang, H., Wang, H., Luo, W., & Liu, T. (2026). Electrochemical Aptamer-Based Sensors for In Vivo Pharmacokinetic Monitoring of Anthracycline Chemotherapeutics: Mechanisms, Stability, and the Clinical Translation Landscape. Electrochem, 7(3), 20. https://doi.org/10.3390/electrochem7030020
Vancouver
Zhang H, Wang H, Luo W, Liu T. Electrochemical Aptamer-Based Sensors for In Vivo Pharmacokinetic Monitoring of Anthracycline Chemotherapeutics: Mechanisms, Stability, and the Clinical Translation Landscape. Electrochem. 2026;7(3):20. doi:10.3390/electrochem7030020
BibTeX
@article{Zhang2026,
author = {Zhang, Haoran and Wang, Huixin and Luo, Wen and Liu, Tao},
title = {Electrochemical Aptamer-Based Sensors for In Vivo Pharmacokinetic Monitoring of Anthracycline Chemotherapeutics: Mechanisms, Stability, and the Clinical Translation Landscape},
journal = {Electrochem},
year = {2026},
volume = {7},
number = {3},
pages = {20},
doi = {10.3390/electrochem7030020}
}
EUVIMED